60,494 Shares in IQVIA Holdings Inc. $IQV Acquired by Lombard Odier Asset Management Europe Ltd

Lombard Odier Asset Management Europe Ltd purchased a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 60,494 shares of the medical research company’s stock, valued at approximately $11,689,000.

Other hedge funds have also recently made changes to their positions in the company. Financial Freedom LLC purchased a new position in shares of IQVIA during the first quarter worth $25,000. Ascentis Independent Advisors acquired a new stake in shares of IQVIA during the first quarter worth about $25,000. International Assets Investment Management LLC purchased a new position in shares of IQVIA in the fourth quarter valued at approximately $27,000. Compass Financial Management LLC purchased a new position in shares of IQVIA in the second quarter valued at approximately $27,000. Finally, Gilpin Wealth Management LLC acquired a new position in shares of IQVIA in the fourth quarter valued at approximately $27,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Insider Buying and Selling at IQVIA

In related news, insider W Richard Staub sold 5,500 shares of the business’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $232.68, for a total value of $1,279,740.00. Following the sale, the insider directly owned 13,312 shares in the company, valued at $3,097,436.16. The trade was a 29.24% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Bhavik Patel sold 1,855 shares of the company’s stock in a transaction dated Friday, July 31st. The shares were sold at an average price of $235.27, for a total transaction of $436,425.85. Following the completion of the sale, the insider directly owned 1,348 shares in the company, valued at $317,143.96. This trade represents a 57.91% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 12,913 shares of company stock valued at $3,098,793 over the last 90 days. 1.70% of the stock is currently owned by corporate insiders.

IQVIA Stock Performance

NYSE:IQV opened at $260.48 on Friday. IQVIA Holdings Inc. has a fifty-two week low of $154.50 and a fifty-two week high of $265.25. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18. The stock has a market cap of $42.88 billion, a PE ratio of 32.32, a price-to-earnings-growth ratio of 2.24 and a beta of 1.18. The firm’s fifty day simple moving average is $222.14 and its 200-day simple moving average is $189.62.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The company had revenue of $4.37 billion during the quarter, compared to the consensus estimate of $4.30 billion. During the same period last year, the firm earned $2.81 EPS. The company’s revenue for the quarter was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Analysts expect that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA announced that its board has initiated a stock repurchase program on Thursday, May 7th that allows the company to buyback $2.00 billion in outstanding shares. This buyback authorization allows the medical research company to buy up to 6.8% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s leadership believes its shares are undervalued.

Wall Street Analyst Weigh In

Several brokerages have weighed in on IQV. Robert W. Baird upped their price target on IQVIA from $252.00 to $287.00 and gave the stock an “outperform” rating in a report on Wednesday, July 29th. Weiss Ratings raised shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, July 15th. TD Cowen increased their price objective on IQVIA from $233.00 to $288.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. Deutsche Bank Aktiengesellschaft set a $240.00 price target on shares of IQVIA in a research note on Thursday, July 9th. Finally, BMO Capital Markets boosted their price target on IQVIA from $210.00 to $270.00 and gave the company an “outperform” rating in a research report on Wednesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $241.88.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.